The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

A Q&A With Shauna Applin, ARNP. AJMC: Despite substantial therapeutic advances since the 1980s, the US is not on pace to achieve the goals of the Ending the HIV Epidemic (EHE) public health initiative ...

Researchers conducted a randomized trial in seven European countries to compare the efficacy and safety of an integrase inhibitor-containing antiretroviral regimen vs a boosted protease ...

A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in hard-to-treat patients. It’s “a potential breakthrough for a growing cohort of ...

Researchers conducted a retrospective, multinational study across 15 European treatment centers to assess the efficacy and tolerability of DTG/3TC vs BIC/TAF/FTC as first‑line therapy in ...

S1: Hey there , San Diego. It's Andrew Bracken in for Jade Hindman. Today , what do cuts in federal funding mean for the future of HIV and Aids programs around the world ? Plus , how progress being ...

What are the three types of HIV tests available to patients, how do they differ, and how can patients determine the best option for them?

ART scale-up to ~80% coverage by 2024 reduced AIDS deaths from ~2 million (2004) to just over 500,000 annually, alongside a 40% decline in incident infections since 2010. Regional divergence is ...